Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools

Launched by PRIMO BIOTECHNOLOGY CO., LTD · Apr 11, 2025

Keywords

ClinConnect Summary

This clinical trial is researching a new imaging tool called PSMA PET that may help doctors better diagnose colorectal cancer that has spread to the liver. The goal is to see how effective this imaging method is for finding liver metastases in patients who already have a diagnosis of colorectal cancer.

To participate in this study, individuals need to be at least 20 years old and must be currently undergoing tests to determine the extent of their cancer after being diagnosed. They should also have confirmed liver metastasis through recent imaging tests like CT scans or MRIs. Participants should be in good enough health to lie still for about two hours during the scanning process. However, those with certain conditions, like multiple organ metastases or severe liver issues, will not be eligible. If you or a loved one meet these criteria, this trial could provide valuable insights into how to improve cancer detection using advanced imaging techniques.

Gender

ALL

Eligibility criteria

• Main inclusion criteria:
• • 1. The participants can voluntarily sign informed consent forms
• • 2. The participants are male/female over 20 years old.
• • 3. The participant is currently undergoing cancer staging based on the previous pathological diagnosis of colorectal cancer
• • 4. The participants are confirmed liver metastasis by CT, abdominal ultrasound, MRI, and FDG PET/CT within 30 days before receiving PSMA-PET/CT.
• • 5. WHO performance status ≦ 2 points
• • 6. The participants can lie on table for two hours during PSMA-PET/CT scanning.
• • Main exclusion criteria: To improve the accurate interpretation of PMSA-PET imaging and reduce the occurrence of related-drug adverse events, the participants will be excluded by following below criteria.
• • 1. The colorectal cancer participants was diagnosed other organs metastases with multiple organ metastases not only the liver.
• • 2. The colorectal cancer participants have undergone any treate after diagnosis of liver metastasis.
• • 3. The participants have suffered from liver dysfunction such as AST/ALT ratio \>2、total bilirubin \>1.5 mg/dL within 6 months.
• • 4. The participants suffered stage IV chronic kidney disease (eGFR\<30 mL/min/1.73 m2) within 6 months.
• • 5. The participants suffered acute kidney injury within 6 months.
• • 6. The participants suffered trauma or fracture.
• • 7. The participants are allergic to any radiopharmaceutical or imaging agent.
• • 8. The participants are history of claustrophobia or are inability to remain quiet during the examination.